Evidence map›Paper›PMID 34632084›Full record

ArticleWellcome open research2020

Cost-effectiveness and public health impact of RTS,S/AS01

Latif Ndeketa, Donnie Mategula, Dianne J Terlouw, Naor Bar-Zeev, Christophe J Sauboin, Sophie Biernaux

Abstract read
In one paragraph

Article in Wellcome open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. RTS,S/AS01 malaria vaccine (MosquirixDrugs & therapy perspectives : for rational drug selection and use · 2022
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Latif NdeketaMalawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi.ORCID https://orcid.org/0000-0002-3376-597X
Donnie MategulaMalawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi.ORCID https://orcid.org/0000-0001-7109-9042
Dianne J TerlouwMalawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi.ORCID https://orcid.org/0000-0001-5327-8995
Naor Bar-ZeevInternational Vaccine Access Center, Department of International Health, 3. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.ORCID https://orcid.org/0000-0003-0570-4624
Christophe J SauboinBoehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim am Rhein, D-55216, Germany.
Sophie BiernauxCoalition for Epidemic Preparedness Innovations, London, NW1 2BE, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cost-effectivenessMalariaMalawiMarkov ChainModellingRTSSvaccine

Identifiers

PMID34632084
PMCPMC8491149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.